Spago Nanomedical: The Tumorad-01 study continues to advance - Redeye

Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is progressing with a steady OPEX base in line with our expectations. The next stage is the DMC feedback based on the first three patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic breast cancer. This could open up to include patients with additional tumour types during the rest of the phase 1 stage.

Länk till analysen i sin helhet: https://www.redeye.se/research/1031983/spago-nanomedical-the-tumorad-01-study-continues-to-advance?utm_source=finwire&utm_medium=RSS